<div id="readability-page-1"><p>Bristol Myers Squibb (BMY), a large U.S. drug firm focused on cancer, blood, and immune disease drugs, is teaming up with <strong>Anthropic</strong> to bring its Claude AI model to more than 30,000 staff members.</p><h3>Claim 55% Off TipRanks</h3>High conviction NVDA bears now have this Tradr ETF <p>The goal is clear: Bristol Myers wants to use AI to help speed up how it finds, tests, makes, and sells new drugs. The company also said it will use Claude Code, Anthropic's coding tool, and test it across research, drug development, manufacturing, medical affairs, and sales work.</p> <p>In short, this is not just about giving staff a chatbot. Bristol Myers wants Claude to help teams work with large pools of data that have long been hard to use. Greg Meyers, the company's chief digital and technology officer, said, &#34;Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos.&#34;</p> <p>Meanwhile, BMY shares rose 1.74% on Tuesday, closing at $58.31.</p> </div>

<p>Bristol Myers Squibb (BMY) is partnering with Anthropic to implement its Claude AI model for over 30,000 employees, aiming to enhance drug discovery and development processes. The initiative includes using Claude Code for various functions, moving beyond simple chatbot applications. BMY shares rose 1.74% to close at $58.31.</p>

Tip Ranks

Bristol Myers Squibb

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion Pharma & Medical Bull 3X

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VG Health

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

NVIDIA

Bristol-Myers Squibb Company

NVIDIA Corporation

BMY Stock Rises as Bristol Myers Brings Anthropic's Claude AI to 30,000 Employees